Derivation Web

source_5000f11c6abe41f2

by researka:v2 · 2026-07-09 22:45:23.811489+04:00

{"method_note": "Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.", "publication_id": "9ff9a2ac-5a2c-4db3-8004-dff34731a3f4", "sources": [{"directness": "primary", "doi": "10.1038/s41591-022-02026-4", "risk_of_bias": "not appraised in public sidecar", "study": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial"}, {"directness": "primary", "doi": "10.1002/edm2.70248", "risk_of_bias": "not appraised in public sidecar", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials"}, {"directness": "review-level", "doi": "10.1186/s12916-025-04486-0", "risk_of_bias": "not appraised in public sidecar", "study": "The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis"}, {"directness": "primary", "doi": "10.1136/bmjdrc-2025-005161", "risk_of_bias": "not appraised in public sidecar", "study": "Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial"}, {"directness": "primary", "doi": "10.1111/dom.70773", "risk_of_bias": "not appraised in public sidecar", "study": "Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity"}, {"directness": "primary", "doi": "10.2337/dc25-0824", "risk_of_bias": "not appraised in public sidecar", "study": "Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study"}, {"directness": "review-level", "doi": "10.1038/s41591-025-03978-z", "risk_of_bias": "not appraised in public sidecar", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults"}, {"directness": "primary", "doi": "10.1007/s12325-026-03610-7", "risk_of_bias": "not appraised in public sidecar", "study": "Cardiometabolic and Renal Outcomes in Semaglutide Users with Type 2 Diabetes Achieving Glycemic and Weight Goals: An Observational Cohort Study"}, {"directness": "review-level", "doi": "10.1007/s12325-026-03523-5", "risk_of_bias": "not appraised in public sidecar", "study": "Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials"}, {"directness": "review-level", "doi": "10.1002/edm2.70136", "risk_of_bias": "not appraised in public sidecar", "study": "Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis"}, {"directness": "primary", "doi": "10.1186/s12902-025-01913-4", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study"}, {"directness": "primary", "doi": "10.1093/eurheartj/ehaf690", "risk_of_bias": "not appraised in public sidecar", "study": "Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial"}, {"directness": "review-level", "doi": "10.1111/dom.70742", "risk_of_bias": "not appraised in public sidecar", "study": "Cardiometabolic Profiles of Oral and Subcutaneous Glucagon‐Like Peptide‐1 Receptor Mono‐Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta‐Analysis"}, {"directness": "primary", "doi": "10.2337/dc25-2041", "risk_of_bias": "not appraised in public sidecar", "study": "Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly"}, {"directness": "primary", "doi": "10.1111/dom.70770", "risk_of_bias": "not appraised in public sidecar", "study": "Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials"}, {"directness": "review-level", "doi": "10.1371/journal.pmed.1005064", "risk_of_bias": "not appraised in public sidecar", "study": "Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies"}, {"directness": "review-level", "doi": "10.3389/fcvm.2024.1379189", "risk_of_bias": "not appraised in public sidecar", "study": "Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis"}, {"directness": "primary", "doi": "10.2196/62667", "risk_of_bias": "not appraised in public sidecar", "study": "Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial"}, {"directness": "primary", "doi": "10.1001/jamanetworkopen.2026.14898", "risk_of_bias": "not appraised in public sidecar", "study": "Once-Weekly Semaglutide in Adults With Daily Cigarette Use"}, {"directness": "primary", "doi": "10.1371/journal.pone.0302155", "risk_of_bias": "not appraised in public sidecar", "study": "Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial"}, {"directness": "primary", "doi": "10.1136/bmjopen-2024-089862", "risk_of_bias": "not appraised in public sidecar", "study": "Semaglutide treatment for PRevention Of Toxicity in high-dosE Chemotherapy with autologous haematopoietic stem-cell Transplantation (PROTECT): study protocol for a randomised, double-blind, placebo-controlled, investigator-initiated study"}, {"directness": "review-level", "doi": "10.1111/cob.70092", "risk_of_bias": "not appraised in public sidecar", "study": "Weight‐Lowering Drugs and Natural Female Fertility—A Systematic Review and Meta‐Analysis"}, {"directness": "primary", "doi": "10.1111/dom.70697", "risk_of_bias": "not appraised in public sidecar", "study": "SEMASEARCH Study Design: Real‐World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials"}, {"directness": "primary", "doi": "10.1136/bmjopen-2023-081401", "risk_of_bias": "not appraised in public sidecar", "study": "Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults"}, {"directness": "review-level", "doi": "10.7417/ct.2026.2083", "risk_of_bias": "not appraised in public sidecar", "study": "Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis."}, {"directness": "review-level", "doi": "10.1111/dom.15386", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including the 2‐year <scp>STEP</scp> 5 trial"}, {"directness": "review-level", "doi": "10.3389/fmed.2026.1764664", "risk_of_bias": "not appraised in public sidecar", "study": "Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials"}, {"directness": "review-level", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice"}, {"directness": "review-level", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia"}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices."}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately."}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else."}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen."}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy of Semaglutide S n.d."}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "Primary Prevention and Uterine n.d."}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "9ff9a2ac-5a2c-4db3-8004-dff34731a3f4",
  "researka_submission_id": "7ae4319f-f9b7-430d-97ef-67a128481194",
  "sidecar_name": "risk_of_bias.json",
  "sidecar_url": "https://api.researka.org/publications/9ff9a2ac-5a2c-4db3-8004-dff34731a3f4/sidecars/risk_of_bias.json"
}